Position in HLN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$557,934
-$39,452 QoQ
Shares Held
59,800
+0.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#183
of 639 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026&PARTNERS holds $18,450,769 across 16 Drug Manufacturers - Specialty & Generic names. HLN ranks #9 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
67,603 | $4,857,951 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
6,447 | $3,493,178 | |
| 3 | VTRS |
Viatris Inc
|
209,068 | $3,319,999 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
13,769 | $1,527,532 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
29,413 | $996,512 | |
| 6 | ELAN |
Elanco Animal Health Inc
|
29,984 | $737,906 | |
| 7 | PBH |
Prestige Consumer Healthcare Inc.
|
13,127 | $620,513 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
37,853 | $606,783 |
All Filings in HLN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $557,934 | 59,800 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $597,386 | 59,679 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $628,083 | 62,125 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $473,032 | 52,735 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $552,389 | 53,268 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $484,103 | 47,046 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $596,602 | 62,537 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $559,893 | 52,920 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $328,417 | 39,760 | Shares | Sole | 2024-07-24 | |
| 2024-03-31 | $106,150 | 12,503 | Shares | Sole | 2024-04-11 | |
| No filing history on record for this holder in this stock. | ||||||